Sorafenib (D06272) is a multi-kinase inhibitor by targeting Raf/MEK/ER pathway, and approved for the treatment of advanced renal cell carcinoma and advanced hepatocellular carcinoma [77]. Here, MAP2K7 is linked to hepatocellular carcinoma.